论文部分内容阅读
目的探讨奥扎格雷钠联合依达拉奉治疗脑梗死对患者血清同型半胱氨酸(HCY)、高敏C-反应蛋白(hs-CRP)、脂蛋白(LP-a)水平的影响。方法将204例脑梗死随机分为研究组和对照组各102例。对照组采用奥扎格雷钠治疗,研究组采用奥扎格雷钠联合依达拉奉治疗。均治疗14d。比较2组患者治疗前后3、7、14d时血清HCY、CRP、LP-a水平差异。结果随着治疗时间的延长,所有患者的血清HCY、CRP、LP-a水平均降低,并低于治疗前各指标的水平,且治疗7d和14d时,以上各指标水平均明显低于治疗前(P<0.05);治疗3d时,研究组患者的HCY、CRP、LP-a的水平均低于对照组,但无显著性差异(P>0.05);治疗7d和14d时,研究组患者的HCY、CRP、LP-a的水平均低于对照组,差异均具有统计学意义(P<0.05)。结论奥扎格雷钠联合依达拉奉治疗脑梗死,可有效降低患者血清HCY、CRP、LP-a水平,有效改善患者的病情,其疗效优于单纯应用奥扎格雷钠治疗。
Objective To investigate the effects of ozagrel combined with edaravone on the serum levels of homocysteine (HCY), hs-CRP and LP-a in patients with cerebral infarction. Methods 204 cases of cerebral infarction were randomly divided into study group and control group of 102 cases. The control group was treated with sodium ozagrel, and the study group was treated with sodium ozagrel combined with edaravone. All treatment 14d. The difference of serum HCY, CRP, LP-a levels before and after 3, 7 and 14 days before and after treatment were compared between the two groups. Results With the extension of treatment time, the serum HCY, CRP and LP-a levels of all the patients were lower than those before treatment, and the levels of the above indexes were significantly lower than those before treatment (P <0.05). At 3 days of treatment, the levels of HCY, CRP and LP-a in study group were lower than those in control group, but there was no significant difference (P> 0.05). On the 7th and 14th day, HCY, CRP, LP-a levels were lower than the control group, the difference was statistically significant (P <0.05). Conclusion Ozagrel combined with edaravone can effectively reduce the levels of serum HCY, CRP and LP-a in patients with cerebral infarction and improve the patient’s condition effectively. The curative effect is better than that of ozagrel alone.